TY - JOUR
T1 - Transfusion requirements and clinical outcome in intensive care patients receiving continuous renal replacement therapy: comparison of prostacyclin vs. heparin prefilter administration
AU - Windeløv, Nis Agerlin
AU - Ostrowski, Sisse R
AU - Perner, Anders
AU - Johansson, Pär I
PY - 2010/7/1
Y1 - 2010/7/1
N2 - Prostacyclin (PGI2) analogous are potent antithrombotics recommended as prefilter infusion during renal replacement therapy (RRT) when heparin is contraindicated. It is debated whether PGI2 administration during RRT affects transfusion requirements and outcome. Retrospective cohort study of all patients at a general intensive care unit (ICU) receiving continuous RRT (CRRT) in a 14-month period. Patients were stratified according to the used anticoagulant, that is prefilter PGI2 group (n = 24) and prefilter heparin group (n = 70). The ICU stay of the patients was divided into three time periods: before, during and after CRRT. For each time period, laboratory values were analysed as changes/day and blood transfusion requirements as absolute values. Organ failures during the ICU stay and 1 year all-cause mortality were registered. During CRRT the PGI2 group had a higher incidence of disseminated intravascular coagulation (DIC) (P = 0.006), severe thrombocytopenia (P = 0.03), higher maximum Sequential Organ Failure Assessment score (P < 0.001) and higher rate of blood transfusions (P = 0.006) compared to the heparin group. However, patients in the PGI2 group tended to have lower mortality rates compared to those in the heparin group (30 days, 21 vs. 39%, P = 0.12; 90 days, 34 vs. 53%, P = 0.10 and 365 days, 38 vs. 57%, P = 0.09). Patients receiving prefilter PGI2 during CRRT were more severely ill and required more blood transfusions. Despite this, a trend towards lower mortality was observed in the PGI2 group suggesting beneficial effects of PGI2 administration in ICU patients undergoing CRRT.
AB - Prostacyclin (PGI2) analogous are potent antithrombotics recommended as prefilter infusion during renal replacement therapy (RRT) when heparin is contraindicated. It is debated whether PGI2 administration during RRT affects transfusion requirements and outcome. Retrospective cohort study of all patients at a general intensive care unit (ICU) receiving continuous RRT (CRRT) in a 14-month period. Patients were stratified according to the used anticoagulant, that is prefilter PGI2 group (n = 24) and prefilter heparin group (n = 70). The ICU stay of the patients was divided into three time periods: before, during and after CRRT. For each time period, laboratory values were analysed as changes/day and blood transfusion requirements as absolute values. Organ failures during the ICU stay and 1 year all-cause mortality were registered. During CRRT the PGI2 group had a higher incidence of disseminated intravascular coagulation (DIC) (P = 0.006), severe thrombocytopenia (P = 0.03), higher maximum Sequential Organ Failure Assessment score (P < 0.001) and higher rate of blood transfusions (P = 0.006) compared to the heparin group. However, patients in the PGI2 group tended to have lower mortality rates compared to those in the heparin group (30 days, 21 vs. 39%, P = 0.12; 90 days, 34 vs. 53%, P = 0.10 and 365 days, 38 vs. 57%, P = 0.09). Patients receiving prefilter PGI2 during CRRT were more severely ill and required more blood transfusions. Despite this, a trend towards lower mortality was observed in the PGI2 group suggesting beneficial effects of PGI2 administration in ICU patients undergoing CRRT.
M3 - Journal article
SN - 0957-5235
VL - 21
SP - 414
EP - 419
JO - Blood Coagulation and Fibrinolysis
JF - Blood Coagulation and Fibrinolysis
IS - 5
ER -